


PHARMACEUTICAL 2022









PHARMACEUTICAL 2022





ENANTA PHARMACEUTICALS INC Rank 98 of 475

The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 131% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is 49%, being 325% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	319,021
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,172
Liabilities, Non-Current	1,684
Other Assets	113,827
Other Compr. Net Income	-1,226
Other Expenses	-28,583
Other Liabilities	1,506
Other Net Income	1,994
Property and Equipment	5,943
Research and Development	174,111
Revenues	97,074
Selling, General and Administrative Expense	32,536

Output Variable	Value in 1000 USD
Assets	438,791
Liabilities	39,362
Expenses	178,064
Stockholders Equity	399,429
Net Income	-78,996
Comprehensive Net Income	-79,609
Economic Capital Ratio	49%